Literature DB >> 23475513

Absence of immunostaining for growth hormone in a subset of patients with acromegaly.

Jason L Schroeder1, Alejandro M Spiotta, Maria Fleseriu, Richard A Prayson, Amir H Hamrahian, Robert J Weil.   

Abstract

The presence of growth hormone (GH) immunostaining in patients who lack the biochemical and clinical features of acromegaly has been described. In contrast, there is little information on the absence of GH immunostaining in patients with acromegaly. We describe five patients with acromegaly with no intratumoral immunostaining for GH. We reviewed all patients undergoing surgery for acromegaly. Out of 136 patients treated surgically in a 10 year period, five (3.7%) were found to have no GH immunostaining on repetitive testing at pathological examination. Their pathology slides were re-examined by an experienced neuropathologist, along with twenty nonfunctional pituitary tumors and ten GH-positive adenomas as negative and positive controls, respectively. All patients had clinical features consistent with acromegaly and elevated baseline insulin-like growth factor-1 (IGF-1) and GH. All patients had no immunostaining for GH on multiple inspections. Of twenty patients with nonfunctional tumors, two had ≤25% staining for GH in a scattered and non-coherent pattern and the rest were negative. In all ten positive control patients >25% of the tumor cells stained diffusely for GH. All five patients achieved biochemical remission at 1.4-8 years post-op using a combination of primary surgery alone (n = 1), repeat surgery (n = 1), radiotherapy (n = 3) and/or medical therapy (n = 2). GH immunostaining of an adenoma may not be sufficient to confirm the diagnosis of acromegaly. All patients in our small series achieved remission by multimodality therapies. Further studies are needed to evaluate the significance of our observation and whether this subset of patients follows a distinct long term clinical course.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 23475513     DOI: 10.1007/s11102-013-0474-4

Source DB:  PubMed          Journal:  Pituitary        ISSN: 1386-341X            Impact factor:   4.107


  26 in total

1.  Epidemiology and long-term survival in acromegaly. A study of 166 cases diagnosed between 1955 and 1984.

Authors:  B A Bengtsson; S Edén; I Ernest; A Odén; B Sjögren
Journal:  Acta Med Scand       Date:  1988

2.  The new WHO classification of human pituitary tumors: comments.

Authors:  Dominique Figarella-Branger; Jacqueline Trouillas
Journal:  Acta Neuropathol       Date:  2005-11-23       Impact factor: 17.088

3.  Somatotropic adenomas without acromegaly.

Authors:  J Trouillas; G Sassolas; B Loras; B Velkeniers; M Raccurt; L Chotard; F Berthezène; J Tourniaire; C Girod
Journal:  Pathol Res Pract       Date:  1991-12       Impact factor: 3.250

4.  Human growth hormone and prolactin secreting pituitary adenomas analyzed by in situ hybridization.

Authors:  R V Lloyd; M Cano; W F Chandler; A L Barkan; E Horvath; K Kovacs
Journal:  Am J Pathol       Date:  1989-03       Impact factor: 4.307

5.  Silent somatotroph adenomas of the human pituitary. A morphologic study of three cases including immunocytochemistry, electron microscopy, in vitro examination, and in situ hybridization.

Authors:  K Kovacs; R Lloyd; E Horvath; S L Asa; L Stefaneanu; D W Killinger; H S Smyth
Journal:  Am J Pathol       Date:  1989-02       Impact factor: 4.307

6.  Significance of growth hormone-releasing hormone receptor mRNA in non-neoplastic pituitary and pituitary adenomas: a study by RT-PCR and in situ hybridization.

Authors:  H Oka; T Kameya; Y Sato; H Naritaka; N Kawano
Journal:  J Neurooncol       Date:  1999-02       Impact factor: 4.130

7.  Prospective evaluation of the characteristics and incidence of adenoma-associated dural invasion in Cushing disease.

Authors:  Russell R Lonser; Alexander Ksendzovsky; Joshua J Wind; Alexander O Vortmeyer; Edward H Oldfield
Journal:  J Neurosurg       Date:  2011-09-16       Impact factor: 5.115

8.  Clinically silent somatotropinomas may be biochemically active.

Authors:  Alla A Sakharova; Eleni V Dimaraki; William F Chandler; Ariel L Barkan
Journal:  J Clin Endocrinol Metab       Date:  2005-01-25       Impact factor: 5.958

9.  Determinants of clinical outcome and survival in acromegaly.

Authors:  C Rajasoorya; I M Holdaway; P Wrightson; D J Scott; H K Ibbertson
Journal:  Clin Endocrinol (Oxf)       Date:  1994-07       Impact factor: 3.478

10.  Mortality in acromegaly: a metaanalysis.

Authors:  O M Dekkers; N R Biermasz; A M Pereira; J A Romijn; J P Vandenbroucke
Journal:  J Clin Endocrinol Metab       Date:  2007-10-30       Impact factor: 5.958

View more
  1 in total

1.  Postoperative GH and Degree of Reduction in IGF-1 Predicts Postoperative Hormonal Remission in Acromegaly.

Authors:  Tyler Cardinal; Casey Collet; Michelle Wedemeyer; Peter A Singer; Martin Weiss; Gabriel Zada; John D Carmichael
Journal:  Front Endocrinol (Lausanne)       Date:  2021-11-18       Impact factor: 5.555

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.